Valuation: Proteomics International Laboratories Ltd

Market Cap 19M 13.3M 11.63M 10.75M 9.87M 18.67M 1.28B 128M 50.37M 626M 49.95M 48.85M 2.16B P/E 2024
-17.4x
P/E 2025 -5.38x
Enterprise Value 8.24M 5.77M 5.04M 4.66M 4.28M 8.1M 556M 55.6M 21.84M 271M 21.66M 21.18M 937M EV / Sales 2024
33.2x
EV / Sales 2025 12.8x
Free-Float
74.46%
Yield 2024 *
-
Yield 2025 -
1 week-9.76%
Current month+60.87%
1 month+42.31%
3 months-32.73%
6 months-75.97%
Current year-71.76%
1 week 0.18
Extreme 0.175
0.2
1 month 0.1
Extreme 0.098
0.22
Current year 0.1
Extreme 0.098
0.86
1 year 0.1
Extreme 0.098
0.86
3 years 0.1
Extreme 0.098
1.4
5 years 0.1
Extreme 0.098
1.4
10 years 0.1
Extreme 0.098
1.48
Manager TitleAgeSince
Chief Executive Officer - 2026-01-18
Director of Finance/CFO - 2026-04-16
Director of Finance/CFO - 2021-07-11
Director TitleAgeSince
Director/Board Member - 2017-11-21
Chairman 56 -
Director/Board Member - 2025-10-13
Date Insider Type Main position Quantity % Market Cap.
11/21/24 Free

Founder

800,000 0.6107%
11/21/24 Free

Founder

800,000 0.6107%
11/21/24 Free

Founder

1,000,000 0.7633%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-9.76%-55.42%-78.86% 21.97M
-3.42%+4.90%+61.15%+87.70% 57.82B
-0.05%-5.85%+54.36%+124.61% 53.71B
-2.14%-9.13%+2.74%+421.65% 23.8B
-0.47%-1.53%-18.61%-15.41% 23.26B
-5.70%-2.37%+30.95%-9.28% 20.7B
-0.29%-2.05%+34.41%-27.98% 17.81B
-4.55%-1.95%+192.65%+349.58% 16.9B
-5.38%-4.59%+28.20%+654.09% 16.36B
+0.23%-2.49%+24.26%+187.16% 13.96B
Average -2.21%+2.38%+35.47%+169.33% 24.44B
Weighted average by Cap. -2.26%-0.15%+46.64%+163.58%

Financials

2024 2025
Net sales 3.28M 2.29M 2.01M 1.85M 1.7M 3.22M 221M 22.11M 8.69M 108M 8.61M 8.43M 373M 3.31M 2.32M 2.03M 1.87M 1.72M 3.26M 223M 22.36M 8.78M 109M 8.71M 8.52M 377M
Net income -6.38M -4.46M -3.9M -3.61M -3.31M -6.27M -430M -43.04M -16.91M -210M -16.76M -16.4M -725M -8.11M -5.68M -4.97M -4.59M -4.21M -7.98M -547M -54.77M -21.52M -267M -21.34M -20.87M -923M
Net Debt -6.32M -4.43M -3.87M -3.58M -3.28M -6.22M -427M -42.68M -16.77M -208M -16.63M -16.26M -719M -10.76M -7.53M -6.58M -6.09M -5.59M -10.58M -726M -72.62M -28.53M -354M -28.29M -27.67M -1.22B
Logo Proteomics International Laboratories Ltd
Proteomics International Laboratories Ltd is an Australia-based medical technology company. The Company is engaged in predictive diagnostics and bioanalytical services. It specializes in the area of proteomics, the industrial scale study of the structure and function of proteins. It focuses on developing and commercializing diagnostic tests for chronic diseases. Its principal activities fall into three key areas: commercialization of PromarkerD, the predictive test for diabetic kidney disease (DKD) and future kidney function decline in patients with type 2 diabetes; precision diagnostic tests in development: the Promarker pipeline, and specialist accredited analytical services on a commercial basis. Its Promarker pipeline and analytical services include PromarkerEndo, PromarkerEso and OxiDx technology. PromarkerEndo is a prototype diagnostic test for endometriosis identifying up to 90% of patients with the disease. PromarkerEso is a prototype diagnostic test for esophageal cancer.
Employees
-
Date Price Change Volume
26-07-16 A$0.1850 0.00% 13,283
26-07-16 A$0.1850 -2.63% 34,863
26-07-15 A$0.1900 -2.56% 114,597
26-07-14 A$0.1950 +5.41% 164,626
26-07-13 A$0.1850 -9.76% 146,611

Annual profits - Rate of surprise